PT  - JOURNAL ARTICLE
AU  - Bablani, Laxman
AU  - Wilson, Tim
AU  - Andrabi, Hassan
AU  - Sundararajan, Vijaya
AU  - Ait Ouakrim, Driss
AU  - Abraham, Patrick
AU  - Thompson, Jason
AU  - Blakely, Tony
TI  - Can a vaccine-led approach end NSW’s outbreak in 100 days, or at least substantially reduce morbidity and mortality?
AID  - 10.1101/2021.08.18.21262252
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.08.18.21262252
4099  - http://medrxiv.org/content/early/2021/08/21/2021.08.18.21262252.short
4100  - http://medrxiv.org/content/early/2021/08/21/2021.08.18.21262252.full
AB  - Background and Aims The New South Wales (NSW) COVID-19 outbreak is at 478 daily cases on August 16, 2021.Our aims were to:estimate the time required to reach ≤5 cases per day under three lockdown strengths (weak, moderate, strong), and four vaccination rollouts: (a) per the original plan, (b) prioritizing essential workers, (c) b plus rapid vaccination of 25% of <60-year-olds with AstraZeneca (AZ25), and (d) b plus rapid vaccination of 50% of <60-year-olds with AstraZeneca (AZ50).estimate the number of cases, hospitalizations, and deaths in the 100 days after 1/August for the 12 scenarios.Methods An agent-based model was adapted to NSW and the Delta variant. Hospitalization and mortality rates for unvaccinated COVID-19 infections were doubled given the virulence of Delta.Results The business-as-usual rollout fully vaccinates 50%, 70% and 80% of >16-year-olds by 10/Oct, 21/Nov, and 28/Dec, respectively. This reduced to 1/Oct, 30/Oct, and 22/Nov for the fastest (AZ50) rollout.A strong lockdown with a rapid vaccine rollout was the fastest to reach ≤5 cases (14-day average), with a median of 78 days (90% Uncertainty interval 61 - 103) or 18/Oct, compared to 207 days (166 - 254) or 24/Feb for a weak lockdown with no rollout acceleration. Increased lockdown strength had more impact than rollout acceleration.Under the AZ25 vaccination scenario, there were 1,440 (90% UI 262 - 10,600 deaths in the first 100 days of cases under a weak lockdown, compared to 71 (90% UI 26 - 178) under a strong lockdown scenario.Conclusion NSW will likely achieve 70% vaccination of >16-year-olds before reaching ≤5 daily cases. Accelerating the vaccine rollout is important for the medium-term, but in the short-term increased restriction strength was more effective at reducing caseload (and subsequently mortality and hospitalisation) than accelerating the vaccine rollout.Significance of Study“The known” NSW is facing a Delta-variant COVID-19 outbreak, with a vaccination-led strategy for controlling the outbreak. Despite the increased infectivity and virulence of the Delta-variant, little contemporaneous modelling exists. We, therefore, model several restrictions and vaccination scenarios.“The new” NSW will likely achieve 70% vaccination of >16-year-olds before daily cases are ≤5. Increased lockdown strength was more effective at reducing cases than accelerating the vaccine rollout.“The implications” Accelerating the vaccine rollout is important in the medium-term, but in the short-term strong public health and social restrictions (including lockdown) are more effective at reining in cases.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialN/AFunding Statementno external funding was received, that should be reported. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis was all publicly available data